Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 32

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 32
---
 Even if we are able to prevent our cryptocurrencies from being considered the property of
a custodian’s bankruptcy estate as part of an insolvency proceeding, it is possible that we would still be delayed or may otherwise
experience difficulty in accessing our cryptocurrencies held by the affected custodian during the pendency of the insolvency proceedings.
Any such outcome could have a material adverse effect on our financial condition and the market price of our listed securities.

<div align='center'>S-18

USE OF PROCEEDS</div>

We may issue and sell shares of our common stock
having aggregate gross proceeds of up to $1,750,000 from time to time. Because there is no minimum offering amount required as a condition
to close this offering, the actual total public offering amount, commissions paid to the Sales Agent and proceeds to us, if any, are not
determinable at this time. We estimate that the net proceeds from the sale of the shares of common stock that we are offering may be up
to approximately $1.6 million, after deducting commissions payable to the Sales Agent and estimated offering expenses payable by us.

We may use the net proceeds from this offering,
if any, for general corporate purposes, which include, among other things, pursuit of the DAT strategy, working capital, capital expenditures,
and/or investing in existing and future projects. We have not yet determined the amount of net proceeds to be used specifically for any
particular purposes or the timing of these expenditures. Accordingly, our management will have significant discretion and flexibility
over the allocation of the net proceeds from this offering, and investors will be relying on our judgment regarding the allocation of
the net proceeds from this offering.

<div align='center'>DIVIDEND POLICY</div>

We have not declared or paid any cash dividends
on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not anticipate
paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the
discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business
conditions and other factors that our board of directors may deem relevant.

<div align='center'>S-19

DILUTION</div>

If you purchase shares of common stock in this
offering, you will experience dilution to the extent of the difference between the public offering price per share in this offering and
our as adjusted pro forma net